{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-349482","form_type":"8-K","ticker":"RNA","cik":"0002093101","company_name":"Atrium Therapeutics, Inc.","filed_at":"2026-08-13T20:50:28+00:00","discovered_at":"2026-08-13T20:51:02.073788+00:00","generated_at":"2026-08-13T20:51:09.780588+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Atrium Therapeutics Q2 2026: IND cleared for ATR 1072, BMS milestone $15M, cash $263.9M","bullets":["FDA cleared IND for ATR 1072; Corventis Phase 1/2 trial in PRKAG2 syndrome launched, ~37 participants planned.","Earned second BMS milestone payment of $15M in August, to be recognized in Q3 2026.","Q2 2026 collaboration revenue $3.0M; R&D expenses $15.3M; G&A $10.3M.","Cash, equivalents and short-term investments $263.9M as of June 30, 2026; runway through mid-2028.","Expect first Corventis participant enrollment by end of 2026; initial data 2H 2027; IND for ATR 1086 in 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-349482","json":"https://secwatch.observer/filing/0001193125-26-349482.json","markdown":"https://secwatch.observer/filing/0001193125-26-349482.md","text":"https://secwatch.observer/filing/0001193125-26-349482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526349482/0001193125-26-349482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526349482/d149126d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:51:09.780588+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}